Alok Srivastava/LinkedIn, Khaled Musallam/LinkedIn
May 6, 2026, 02:23
Khaled Musallam: When the Worlds of Thalassemia and Hemophilia Converge
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, shared a post on LinkedIn:
“When the worlds of thalassemia and hemophilia converge, impactful advances are inevitable.
Delighted to welcome Prof Alok Srivastava as Visiting Professor, Consultant Hematologist, and Deputy Chief of Cell and Gene Therapy and Hematology at Burjeel Cancer Institute.
Excited for what lies ahead as we build robust services and bring forward innovative therapies for patients with blood disorders.”
More posts featuring Khaled Musallam on Hemostasis Today.
-
May 6, 2026, 12:53Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
-
May 6, 2026, 12:36Alan Nurden: CRISPR-Mediated Megakaryocyte Modeling in Glanzmann Thrombasthenia
-
May 6, 2026, 12:12Mona Ranade: Insights from a Medeloop Analytics Study Evaluate Catheter-Directed Therapy in Pulmonary Embolism
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading
-
May 6, 2026, 02:58Limiaa Babikir: What Is Polyspecific DAT?